Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease.
Anti-MDA antibody
Clinically amyopathic dermatomyositis
Dyspnea
Hypoxia
Idiopathic inflammatory myositis
Myositis specific antibody
Rapidly progressive interstitial lung disease
Journal
Journal of medical cases
ISSN: 1923-4163
Titre abrégé: J Med Cases
Pays: Canada
ID NLM: 101551824
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
01
06
2022
accepted:
07
07
2022
entrez:
21
9
2022
pubmed:
22
9
2022
medline:
22
9
2022
Statut:
ppublish
Résumé
Anti-melanoma differentiation-associated protein 5 (anti-MDA5) associated clinically amyopathic dermatomyositis (CADM) is a rare entity that is frequently associated with rapidly progressive interstitial lung disease. The disease is characterized by its association with a distinct myositis specific antibody, the lack of muscle involvement seen with other inflammatory myopathies, and a strong correlation with the development of rapidly progressive interstitial lung disease. Diagnosis is based on clinical findings and the presence of autoantibodies. Management generally involves combination immunosuppression therapy. However, the disease course is often aggressive and lends a poor prognosis. We report a case of a healthy 55-year-old male who presented with dyspnea, dry cough, and joint pain for 1 month. The patient was diagnosed with anti-MDA5 associated CADM with interstitial lung disease after a complete rheumatological workup found elevated titers of MDA5 antibodies and computed tomography of the chest without contrast revealed radiographic evidence of interstitial lung involvement. Disease course was complicated by the development of
Identifiants
pubmed: 36128070
doi: 10.14740/jmc3965
pmc: PMC9451563
doi:
Types de publication
Case Reports
Langues
eng
Pagination
374-379Informations de copyright
Copyright 2022, Tavakolian et al.
Déclaration de conflit d'intérêts
None to declare.
Références
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1316-24
pubmed: 23908005
Rheumatology (Oxford). 2020 Nov 1;59(11):3284-3292
pubmed: 32276271
Rheumatol Int. 2018 Jul;38(7):1293-1296
pubmed: 29417209
Ann Rheum Dis. 2017 Dec;76(12):1955-1964
pubmed: 29079590
N Engl J Med. 2019 Jul 18;381(3):291-293
pubmed: 31314977
Rheumatology (Oxford). 2018 Dec 1;57(12):2114-2119
pubmed: 30060040
Chest. 2009 Nov;136(5):1341-1347
pubmed: 19581351
N Engl J Med. 1975 Feb 20;292(8):403-7
pubmed: 1089199
Arthritis Rheum. 2005 May;52(5):1571-6
pubmed: 15880816
Ann Rheum Dis. 2014 Aug;73(8):1591-3
pubmed: 24739327
Curr Treatm Opt Rheumatol. 2021;7(4):319-333
pubmed: 34603940
J Am Acad Dermatol. 2020 Feb;82(2):267-281
pubmed: 31279808
Rheumatology (Oxford). 2020 Apr 1;59(4):767-771
pubmed: 31504956
J Gen Intern Med. 2021 Dec;36(12):3865-3868
pubmed: 34561830
J Dermatol. 2020 May;47(5):483-489
pubmed: 32096271
Sci Rep. 2016 Sep 12;6:33226
pubmed: 27615411
Arthritis Rheumatol. 2020 Mar;72(3):488-498
pubmed: 31524333
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
Rheumatology (Oxford). 2012 Jul;51(7):1336-8
pubmed: 22361226